Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13045-017-0473-4 http://scihub22266oqcxt.onion/10.1186/s13045-017-0473-4 C5427576!5427576!28494772     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28494772&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Hematol+Oncol 2017 ; 10 (ä): ä Nephropedia Template TP {{tp|p=28494772|t=2017. Anti-claudin 18 2 antibody as new targeted therapy for advanced gastric cancer |pdf=|usr=}}{{28494772}} gab.com Text Anti-claudin 18 2 antibody as new targeted therapy for advanced gastric cancer JO: J Hematol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=28494772 #FOAvip Targeted therapy and immunotherapy have revolutionized treatment of various cancers in the past decade. Despite targeted therapy with trastuzumab in Her2-positive gastric cancer patients, survival has been dismal, mostly due to disease progression and toxicity related to the treatments. One area of active development is looking for ideal monoclonal antibodies (IMAB) specific to the proteins only on the tumor and hence avoiding unnecessary side effects. Claudin proteins with isoform 2 are one such protein, specific for several cancers, particularly gastric cancer and its metastases, leading to the development of anti-claudin 18.2 specific antibody, claudiximab. This review will highlight the latest development of claudiximab as first in class IMAB for the treatment of gastric cancer. Twit Text FOAVip Anti-claudin 18 2 antibody as new targeted therapy for advanced gastric cancer ????J Hematol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=28494772 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28494772 #FOAvip English Wikipedia <ref>{{Cite pmid|28494772}}</ref> Anti-claudin 18 2 antibody as new targeted therapy for advanced gastric cancer #MMPMID28494772 Singh P; Toom S; Huang Y J Hematol Oncol 2017[]; 10 (ä): ä PMID28494772show ga Targeted therapy and immunotherapy have revolutionized treatment of various cancers in the past decade. Despite targeted therapy with trastuzumab in Her2-positive gastric cancer patients, survival has been dismal, mostly due to disease progression and toxicity related to the treatments. One area of active development is looking for ideal monoclonal antibodies (IMAB) specific to the proteins only on the tumor and hence avoiding unnecessary side effects. Claudin proteins with isoform 2 are one such protein, specific for several cancers, particularly gastric cancer and its metastases, leading to the development of anti-claudin 18.2 specific antibody, claudiximab. This review will highlight the latest development of claudiximab as first in class IMAB for the treatment of gastric cancer. äAnti-claudin 18 2 antibody as new targeted therapy for advanced gastri(epmc).pdf DeepDyve Pubget Overpricing